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Abstract 
 
Background  
Visual hallucinations (VH) occur in the clinical course of Parkinson’s disease (PD) and are predictive for 
the development of psychosis and PD dementia. The genesis of VH is related to impaired bottom-up 
and/or top-down visual processing which have been linked to cholinergic dysfunction and mono-amine 
imbalance. The risk of developing VH with oral dopamine agonists seems to increase with advancing 
disease while evidence suggests that in contrast apomorphine is well-tolerated. Beneficial effects of 
apomorphine on VH have also been reported. 
Methods 
The aim of this study is to review current evidence relating to apomorphine and VH in relation to its 
mode of action.  
Results 
There is little evidence on the efficacy of apomorphine on VH suggesting a positive effect due to the 
action of its piperidine moiety. This moiety is also found in many anti-psychotics, and has binding sites to 
specific dopaminergic and serotonergic receptors (5-HT2A). The potential anti-hallucinogenic effect might 
be related to mixed D1 and D2–like receptor agonism and serotonin 5-HT2A receptor antagonism. 
Conclusion 
It is very likely that the genesis of VH in PD is related to multiple deficient mono-aminergic systems.  It is 
possible that the anecdotal evidence suggesting that apomorphine has a relatively low proclivity to 
induce VH in PD may be due to its capacity to reduce serotonergic activity and simultaneously enhance 
dopaminergic transmission.  
  
Introduction 
Visual hallucinations (VH) occur commonly in Parkinson’s disease (PD) with an estimated prevalence of 
22-38%, increasing up to more than 60% after long-term follow-up [1,2]. The most significant risk factors 
in the development of VH include disease duration, motor symptom severity and cognitive impairment. 
They become increasingly intrusive in many patients and are believed to be predictive for PD dementia 
[1].  
 
VH have long been considered a side-effect of dopaminergic medication, based on clinical experience 
and an early open-label trial [3]. However, in spite of several studies no strong link has been identified 
between the occurrence of VH and the dosage or duration of dopaminergic medication [1,4,5]. 
Moreover, VH have also been reported in a few drug-naïve PD patients [6–8]. This suggests that VH are 
not directly caused by dopaminergic overstimulation, but that treatment may act as a precipitating 
factor. In contrast, evidence from a number of case series and a single open-label prospective trial 
suggest that apomorphine (potent dopamine agonist) has the potential to alleviate some of the 
symptoms of VH [9–12].  
 
We examine the current evidence for the underlying pathogenesis of VH in PD,  together with the 
impact of dopamine agonists in general and apomorphine in particular.  
 
Pathogenesis of visual hallucinations in Parkinson’s disease 
Collerton and colleagues have proposed the perception and attention deficit (PAD) model, suggesting 
that VH are caused by disruption of either the bottom-up and/or top-down visual processing 
mechanisms  [13]. In bottom-up processing, visual stimuli reaching the primary cortex are coupled to 
specific content e.g. shape, colour, and motion. For object recognition, information from the primary 
visual cortex is further processed in the inferior temporal cortex via the ventral visual stream [14]. The 
information received in the parietal lobe provides detail of the spatial content of the visual stimulus, 
referred to as the dorsal stream. In top-down processing, an interpretation of the visual information is 
generated based on perceptual expectations and prior knowledge. Visual information from the inferior 
temporal cortex is dealt with in the lateral prefrontal cortex via the uncinate fascicle [15], and via 
cortico-thalamo-cortical loops [16–18]. The  mediodorsal and reticular thalamic nuclei are essential in 
gating and filtering relevant visual information [19,20].  
 
Impaired bottom-up and top-down visual processing in PD patients with VH is supported by structural 
and functional imaging [14], and clinico-pathological studies [15]. PD patients with VH were found to 
have impaired attention and higher cortical visuoperception, due to prefrontal cortex and parieto-
occipital cortex dysfunction respectively on functional imaging [16–19], and higher Lewy body density 
and alpha-synuclein aggregation was found in prefrontal, temporal and visuoperceptive areas in patients 
with coexistent PD and VH than age matched controls without VH [20–23]. 
 
Central to the PAD modelVisual processing and VH have been linked to dysfunctional neurotransmitter 
systems is the connection between visual processing, VHs and cholinergic dysfunction [13,16]. Although 
the majority of the pathophysiological evidence for VH involves disruption of the cholinergic system, 
there is also support for a dysbalance in mono-aminergic neurotransmitter systems, especially related to 
dopamine and serotonin.  
 
The role of acetylcholine, dopamine and serotonin in the development of 
visual hallucinations 
 
a) Acetylcholine 
 
Bottom-up and top-down visual pathways are modulated by acetylcholine. Low cholinergic activity 
following the use of anticholinergic drugs impairs attention [17,18] and visual processing [19], and can 
sometimes induce delirium with VH, even in individuals without clinical evidence of PD (Han et al., 2001) 
[20]. In contrast, use of cholinesterase inhibitors improves attention, thalamic function and visual 
processing in a dose-dependent manner [17,21–23].  
 
The majority of cholinergic projections to the cortex originate from the nucleus basalis of Meynert 
(NBM), located in the basal forebrain, and from the pedunculopontine nucleus (PPN), projecting to the 
thalamus. Comparison of PD patients with and without VH has found greater degeneration of these 
regions in those with VH [24–26]. There is little in vivo clinical data of cholinergic activity in PD patients 
with VH with cortical cholinergic activity reduced in PD patients with dementia (PDD) compared to those 
without and a greater clinical response to cholinesterase inhibitors in these patients with VH compared 
to those without hallucinations [27–29]. An ongoing randomized, placebo-controlled, double-blind 
phase IV study is currently investigating the effect of rivastigmine in PD patients with VH without 
dementia (NCT01856738).  
 
a)b) Dopamine 
 
The substantia nigra and ventral tegmental area (VTA) are the major source of dopamine in the brain. 
The substantia nigra primarily projects to the dorsal striatum, whereas the VTA projects to the ventral 
striatum and to extrastriatal regions, including the prefrontal cortex, mediodorsal nucleus and lateral 
geniculate nucleus of the thalamus and occipital cortex [44–49]. These projections target both D1-like 
receptors (abundant in the prefrontal cortex) and D2-like receptors (high density in the striatum)[50,51]. 
The rich expression of D1-like receptors in the prefrontal cortex suggests a key role in top-down 
processes related to attention, a feature supported by a number of animal studies [30,31]. Absence of 
selective  D1 agonists and antagonists has complicated study of these specific receptors in humans. 
However, genetic variation in the breakdown of prefrontal dopamine by the catechol-O-
methyltransferase (COMT) gene has made it possible to compare high-activity (low dopamine) and low-
activity (high dopamine) COMT genotypes. Results from both animal and genetic studies suggest an 
inverted U-shaped relationship between D1-like receptor activity and prefrontal function (Figure 2), with 
both low and high dopaminergic activity impairing function of the prefrontal regions, clinically 
manifesting as reduced working memory and attention [32,33]. In other words, the optimal prefrontal 
performance is achieved with intermediate dopaminergic activity and whether stimulation or inhibition 
of D1-like receptors yields this optimum depends on the baseline dopaminergic activity in the prefrontal 
cortex. Enhanced dopamine levels are found in early PD patients resulting in impaired prefrontal 
functioning [34–36] presumably due to frontal compensation [37]. With disease progression, the 
number of prefrontal D1-like receptors is reduced and prefrontal functioning deteriorates [36,38–40]. 
 
Dopamine may play a role in visual processing. It is well recognized that dopamine deficiency in the 
occipital cortex, lateral geniculate nucleus and retina impairs lower-order visual functions, such as color 
discrimination and visual contrast sensitivity, as well as playing a role in higher-order visual functions, 
such as motion perception, visual acuity, and colour vision [41]. These deficits can be reversed with the 
administration of levodopa [41], suggesting a compelling link between dopamine and visual perception. 
Dopamine appears to play a more specific role in retinal function with concentrations sensitive to light 
intensity and a circadian rhythm with lower dopamine concentrations at night and higher levels during 
the day [41]. Therefore, dopamine seems to be essential in mediating light-adaptive mechanisms in 
retinal function [42,43]. 
 
Overall, the stimulation of D1-like and D2-like receptors by apomorphine may have different effects on 
top-down processing, dependent upon concentration of the drug and the clinical disease stage (Figure 
2). In early PD, where a relative dopaminergic overstimulation in the prefrontal cortex exists, the 
addition of apomorphine could potentially worsen top-down processing. However, in late PD a relative 
shortage of dopamine in the prefrontal cortex may be corrected by apomorphine administration. These 
findings suggest that other mixed D1-like and D2-like dopamine agonists, such as pergolide and 
cabergoline, could exert similar anti-hallucinogenic effects. However, the evidence to date suggest a 
distinct effect for the ergolines pergolide and cabergoline indicating that the serotonergic antagonistic 
properties of apomorphine’s piperdine moiety makes an additional and significant contribution [66]. 
 
b)c) Serotonin 
 
Accumulation of alpha-synuclein and Lewy body pathology is also found in serotonergic neurons located 
in the raphe nucleus [67]. The median, and to a lesser extent, the dorsal raphe nuclei project directly to 
the prefrontal cortex, occipital cortex and thalamic nuclei, and indirectly via the striatum [68,69], all 
potentially having a role in visual processing.  
 
The serotonergic receptor 5-HT2A is widely expressed in the neocortex and suggested to play a role in 
the pathogenesis of VH.  Positron emission tomography (PET) studies comparing PD patients with and 
without VH demonstrated an increased 5-HT2A binding in prefrontal and visual processing areas [44,45]. 
A potential explanation for these findings being compensatory post-synaptic up-regulation due to pre-
synaptic serotonergic neuronal loss. Neurochemical studies using the 5-HT2A receptor agonist, 
psilocybin, have also demonstrated a dose-dependent reduction in prefrontal functions (e.g. attention 
and working memory) and in visuo-perceptive functions (e.g. high-level motion perception) as well as 
inducing VH in healthy volunteers [46–49]. Interestingly functional imaging studies have demonstrated 
similar activation patterns in healthy volunteers with psilocybin-induced hallucinations as those seen in 
PD patients with VH with reduced activity in the occipital cortex and visual pathways, as well as 
increased activation in the prefrontal cortex [50–53].  Subsequent studies have made use to the 5-HT2A 
receptor antagonist ketanserin, used to block the effects of psilocybin in healthy volunteers [47,48,54]. 
These findings, together with the successful use of clozapine in the treatment of PD-related VH (due to 
predominant 5-HT2A receptor antagonist activity) suggests that treatment of these symptoms in patients 
with VH might benefit from wider therapy with 5-HT2A receptor antagonists [55]. Use of the selective 5-
HT2A antagonist pimavanserin has been shown to resolve psychotic behavior in an animal model (6-
hydroxydopamine), while in clinical trials use of pimavanserin, previously demonstrated to be well 
tolerated, has more recently been reported to have a beneficial effect on VH in PD patients [56–58].  
 
Although the majority of the pathophysiological evidence for VH involves disruption to acetylcholine 
transmission, there is also support for a role of mono-amine neurotransmitters indicating a need for 
adaption to the PAD model, particularly in relation to the role of dopamine agonists, most notably 
apomorphine.  
 
Clinical evidence for the risk of development of visual hallucinations 
with medical therapiesrelated to dopaminomimetics 
 
a) Oral dopamine agonists and rotigotine transdermal patch 
 
Anecdotal clinical experience and a number of clinical trials have suggested that oral dopamine agonists 
may exacerbate and unmask VH. In a 2010 meta-analysis the use of dopamine agonists including 
pergolide (RR 4.80, 95% confidence interval (CI): 2.24, 10.29), rotigotine (RR 4.02, 95%CI: 1.23, 13.11), 
pramipexole (RR 3.36, 95%CI: 2.41, 4.68), ropinirole (RR 2.84, 95%CI: 1.34, 5.99), cabergolide (RR 1.56, 
95%CI: 0.47, 5.21) and bromocriptine (RR 1.10, 95%CI: 0.37, 3.26) was associated with a higher relative 
risk (RR) of VH compared to placebo [59]. However, no adjustment was made for disease duration, age 
or cognition, all of which are likely to impact on the development of VH. Studies have shown that use of 
dopamine agonists in patients >70 years of age is associated with an increased risk of developing VH 
compared to younger patients [5], while a recent meta-analysis demonstrated that the RR of developing 
VH increased to 5.24 (95%CI: 2.42, 11.35) in advanced PD patients (age of 61-66 years, disease duration 
of 5.9-8.9 years) using dopamine agonists on top of levodopa treatment [60].  
 
In contrast to the possible increased risk of dopamine agonists infusion of high-dose levodopa failed to 
precipitate visual hallucinations in non-demented PD patients [61], and low- dose dopaminergic 
treatment is rarely complicated with the development of visual hallucinations in other disorders, such as 
hyperprolactinaemia, raising the possibility that cholinergic and/or serotonergic dysfunction is an 
essential prerequisite for their occurrence.   
 
It is therefore recommended that in the absence of systemic illness, the dose of dopamine agonist 
should be reduced if VH develop and that they should be prescribed with caution in PD patients with 
significant cognitive impairment [62].  
 
b) Apomorphine 
 
No worsening of VH has been reported in advanced PD patients receiving apomorphine treatment with 
long-term follow-up in descriptive studies [63–66] and apomorphine has even been suggested to have a 
beneficial effect on VH [9,12]. The antipsychotic potential of apomorphine was first reported in patients 
diagnosed with schizophrenia [67,68]. In a double-blind, placebo-controlled trial 3 mg subcutaneously-
administered apomorphine reduced psychotic symptoms in 18 patients with longstanding schizophrenia 
[68]. This reduction in psychotic symptoms has also been replicated in several open and controlled trials 
of the management of acute psychosis patients diagnosed with schizophrenia [69].  
 
The beneficial effects of apomorphine in the treatment of neuropsychiatric symptoms (predominantly 
VH) in patients with PD have been reported in a number of case series [9–11]. Altogether these case 
series describe long-term follow-up (8-72 months) of 16 PD patients, 12 with reported VH. Eleven 
described a dramatic reduction in visual symptoms with only mild persistence in the remaining case [9]. 
Support for these observations has come from a more recent open-label clinical trial, in which treatment 
with oral dopamine agonists was replaced with apomorphine [12]. PD patients with VH (n=8) 
demonstrated an improvement in neuropsychiatric symptoms (measured using the Neuropsychiatric 
Inventory Questionnaire (NPI-Q), evident after only a week of apomorphine treatment and persisting six 
weeks later. These findings suggest that apomorphine may be prescribed in PD patients with VH 
provided there is concomitant reduction in the dose of oral dopamine agonists and/or adequate 
treatment of existing cognitive deficits [12].  
 
In spite of this evidence, the common clinical perception remains that apomorphine has the proclivity 
like other dopamine agonists to worsen VH in patients with PD [70]. This may be in part due to those 
early anecdotal descriptions of worsening neuropsychiatric symptoms and the absence of a randomized 
controlled trial of the impact of apomorphine on VH [71–73].  
 
Chemical structure and receptor binding profile of apomorphine 
 
The molecular structure of apomorphine is closely related to dopamine (Figure 1), sharing a benzene 
ring with two hydroxyl groups, but it also contains a piperidine moiety ((CH2)5NH), which may be crucial 
for its proposed antipsychotic effect [74]. This piperidine moiety is also incorporated in the chemical 
structure of many antipsychotic medications, including piperidine phenothiazines, haloperidol, 
risperdone, bulbocapnine and other aporphines [75,76]. Based on the structural similarities, it has been 
argued that the antipsychotic potential of apomorphine is due to the specific action of this piperidine 
moiety in binding to dopaminergic and serotonergic receptors (particularly 5-HT2A-receptors), producing 
an antagonistic effect [9,12,76–78].  
 
Apomorphine is a strong dopamine agonist possessing high affinity for both D1-like (D1 and D5) and D2-
like (D2, D3, and D4) receptors [79]. It also possesses antagonist activity at 5-HT2A receptors and agonist 
activity at norepinephrine receptors, although affinity at both receptors is relatively weak [80,81]. In 
order to determine the role of the receptor profile of apomorphine, mono-aminergic projections need 
to be incorporated into the PAD model of VH. 
 
Overall, the stimulation of D1-like and D2-like receptors by apomorphine may have different effects on 
top-down processing, dependent upon concentration of the drug and the clinical disease stage (Figure 
2). In early PD, where a relative dopaminergic overstimulation in the prefrontal cortex exists, the 
addition of apomorphine could potentially worsen top-down processing. However, in late PD a relative 
shortage of dopamine in the prefrontal cortex may be corrected by apomorphine administration. These 
findings suggest that other mixed D1-like and D2-like dopamine agonists, such as pergolide and 
cabergoline, could exert similar anti-hallucinogenic effects. However, the evidence to date suggest a 
distinct effect for the ergolines pergolide and cabergoline indicating that the serotonergic antagonistic 
properties of apomorphine’s piperdine moiety makes an additional and significant contribution [59]. 
 
The role of mono-amines in the development of visual hallucinations 
 
c) Dopamine 
 
The substantia nigra and ventral tegmental area (VTA) are the major source of dopamine in the brain. 
The substantia nigra primarily projects to the dorsal striatum, whereas the VTA projects to the ventral 
striatum and to extrastriatal regions, including the prefrontal cortex, mediodorsal nucleus and lateral 
geniculate nucleus of the thalamus and occipital cortex [66–71]. These projections target both D1-like 
receptors (abundant in the prefrontal cortex) and D2-like receptors (high density in the striatum)[72,73]. 
The rich expression of D1-like receptors in the prefrontal cortex suggests a key role in top-down 
processes related to attention, a feature supported by a number of animal studies [74,75]. Absence of 
selective  D1 agonists and antagonists has complicated study of these specific receptors in humans. 
However, genetic variation in the breakdown of prefrontal dopamine by the catechol-O-
methyltransferase (COMT) gene has made it possible to compare high-activity (low dopamine) and low-
activity (high dopamine) COMT genotypes. Results from both animal and genetic studies suggest an 
inverted U-shaped relationship between D1-like receptor activity and prefrontal function (Figure 2), with 
both low and high dopaminergic activity impairing function of the prefrontal regions, clinically 
manifesting as reduced working memory and attention [76,77]. In other words, the optimal prefrontal 
performance is achieved with intermediate dopaminergic activity and whether stimulation or inhibition 
of D1-like receptors yields this optimum depends on the baseline dopaminergic activity in the prefrontal 
cortex. Enhanced dopamine levels are found in early PD patients resulting in impaired prefrontal 
functioning [78–80] presumably due to frontal compensation [81]. With disease progression, the 
number of prefrontal D1-like receptors is reduced and prefrontal functioning deteriorates [80,82–84]. 
 
Dopamine may play a role in visual processing. It is well recognized that dopamine deficiency in the 
occipital cortex, lateral geniculate nucleus and retina impairs lower-order visual functions, such as color 
discrimination and visual contrast sensitivity, as well as playing a role in higher-order visual functions, 
such as motion perception, visual acuity, and colour vision [85]. These deficits can be reversed with the 
administration of levodopa [85], suggesting a compelling link between dopamine and visual perception. 
Dopamine appears to play a more specific role in retinal function with concentrations sensitive to light 
intensity and a circadian rhythm with lower dopamine concentrations at night and higher levels during 
the day [85]. Therefore, dopamine seems to be essential in mediating light-adaptive mechanisms in 
retinal function [86,87]. 
 
Overall, the stimulation of D1-like and D2-like receptors by apomorphine may have different effects on 
top-down processing, dependent upon concentration of the drug and the clinical disease stage (Figure 
2). In early PD, where a relative dopaminergic overstimulation in the prefrontal cortex exists, the 
addition of apomorphine could potentially worsen top-down processing. However, in late PD a relative 
shortage of dopamine in the prefrontal cortex may be corrected by apomorphine administration. These 
findings suggest that other mixed D1-like and D2-like dopamine agonists, such as pergolide and 
cabergoline, could exert similar anti-hallucinogenic effects. However, the evidence to date suggest a 
distinct effect for the ergolines pergolide and cabergoline indicating that the serotonergic antagonistic 
properties of apomorphine’s piperdine moiety makes an additional and significant contribution [43]. 
 
d) Norepinephrine 
 
Norepinephrine is predominantly synthesized in the locus coeruleus. Noradrenergic axons have 
widespread projections to the thalamus, hippocampus, amygdala, VTA, pontine tegmentum, and 
prefrontal cortex with norepinephrine itself having highest affinity for alpha-2 adrenergic receptors 
[88,89].  
 
The effects of norepinephrine on prefrontal functions also follow an inverted U-shaped curve [90]. 
Modulation of alpha-2 adrenergic receptors in healthy volunteers revealed inconsistent effects on 
prefrontal functions [91–93]. In contrast, patients with a presumed prefrontal norepinephrine deficiency 
(i.e. attentional deficit hyperactivity disorder (ADHD) and schizophrenia) were noted to improve with 
alpha-2 adrenergic stimulation. Clonidine and guanficine (alpha-2 adrenergic receptor agonists), 
improved attention and working memory in patients diagnosed with ADHD and schizophrenia [94–96]. A 
single study has examined the effect of norepinephrine on working memory in patients with PD with use 
of clonidine [97]. Here the effect was greatest in those with advanced PD compared to early 
symptomatic individuals, supporting this inverted-U relationship between norepinephrine and 
prefrontal functioning [97].  
 
There is no currently available data of the effect of norepinephrine on visual perception demonstrating 
an area with need for further investigation. 
 
e) Serotonin 
 
Accumulation of alpha-synuclein and Lewy body pathology is also found in serotonergic neurons located 
in the raphe nucleus [98]. The median, and to a lesser extent, the dorsal raphe nuclei project directly to 
the prefrontal cortex, occipital cortex and thalamic nuclei, and indirectly via the striatum [99,100], all 
potentially having a role in visual processing.  
 
The serotonergic receptor 5-HT2A is widely expressed in the neocortex and suggested to play a role in 
the pathogenesis of VH.  Positron emission tomography (PET) studies comparing PD patients with and 
without VH demonstrated an increased 5-HT2A binding in prefrontal and visual processing areas 
[101,102]. A potential explanation for these findings being compensatory post-synaptic up-regulation 
due to pre-synaptic serotonergic neuronal loss. Neurochemical studies using the 5-HT2A receptor 
agonist, psilocybin, have also demonstrated a dose-dependent reduction in prefrontal functions (e.g. 
attention and working memory) and in visuo-perceptive functions (e.g. high-level motion perception) as 
well as inducing VH in healthy volunteers [103–106]. Interestingly functional imaging studies have 
demonstrated similar activation patterns in healthy volunteers with psilocybin-induced hallucinations as 
those seen in PD patients with VH with reduced activity in the occipital cortex and visual pathways, as 
well as increased activation in the prefrontal cortex [20,107–109].  Subsequent studies have made use 
to the 5-HT2A receptor antagonist ketanserin, used to block the effects of psilocybin in healthy 
volunteers [104,105,110]. These findings, together with the successful use of clozapine in the treatment 
of PD-related VH (due to predominant 5-HT2A receptor antagonist activity) suggests that treatment of 
these symptoms in patients with VH might benefit from wider therapy with 5-HT2A receptor antagonists 
[111]. Use of the selective 5-HT2A antagonist pimavanserin has been shown to resolve psychotic 
behavior in an animal model (6-hydroxydopamine), while in clinical trials use of pimavanserin, previously 
demonstrated to be well tolerated, has more recently been reported to have a beneficial effect on VH in 
PD patients [112–114].  
  
Discussion 
 
Apomorphine appears to increase lower-order visual perception (e.g. contrast sensitivity), while higher-
order perceptual functions (e.g. color perception, visual acuity, visual object, and space perception) 
remain unchanged. A decrease in contrast sensitivity was found after infusion of apomorphine in 
healthy volunteers [82,83], suggesting that overstimulation of retinal or cortical dopamine receptors 
may result in reduced lower-order visual perception. The absence of a positive effect on higher-order 
perceptual functions in PD patients with VH might be related to a dosing- or a ceiling effect. Conflicting 
results have been reported in the effect of apomorphine on attention, this variability potentially being 
related to the clinical stage of PD, although distinct outcome measures and lack of adjunctive clinical 
data (e.g. use and dosing of other medical therapies) may also have contributed [64,65,84,85].  
 
The beneficial effect of apomorphine in the treatment of VH is based on limited available data and lacks 
prospectively designed randomized controlled trials. However, it does appear that unlike oral dopamine 
agonists, apomorphine does not exacerbate symptoms in PD patients with pre-existing VH [12,63–65]. 
An additional benefit of apomorphine might be its modifying effect on amyloid deposition [86]. 
 
Based on the PAD model several deficient mono-aminergic systems may induce VH in PD. Therefore, the 
treatment of VH in PD will very likely require a combination of therapies dependent on the balance of 
mono-amines. A combination of apomorphine with cholinesterase inhibitors should be considered in 
patients who have developed refractory VH on oral dopamine agonist therapy and who cannot 
withdraw them without substantial deterioration in motor performance.  
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Table 1. Receptor affinity of dopamine agonists. Adapted from Deleu et al. (2004) 
 D1 D2 5-HT2A α2 
Aporphines     
Apomorphine ++ +++ - ++ 
Ergot derivatives     
Bromocriptine - +++ ++ ++ 
Cabergoline + +++ +++ + 
Lisuride - +++ ++ + 
Pergolide + +++ +++ ++ 
Nonergoline derivatives     
Piribedil + +++ 0 NA 
Pramipexole 0/+ +++ 0/+ + 
Ropinirole 0 +++ 0/+ 0 
Rotigotine ++ +++ NA NA 
D = dopamine receptor; 5-HT = serotonin receptor; α = α-adrenergic receptor; NA = information not 
available; - indicates antagonist activity; 0 indicates no affinity; + indicates low affinity; ++ indicates 
moderate affinity; +++ indicates high affinity. 
 
 
  
Figure 1. The chemical structure of dopamine (left) and apomorphine (right). Note the piperidine 
moiety. 
 
  
Figure 2 : Relationship between prefrontal functioning and dopamine level in prefrontal cortex 
 
WM : working memory. Val/val: high-activity COMT genotype. Met/met: low-activity COMT genotype. 
Note that moderate dopamine levels in the prefrontal cortex (PFC) yields optimal prefrontal 
performance. Adapted from Williams-Gray [36]. 
